There are currently 809 clinical trials in Detroit, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Henry Ford Hospital, Henry Ford Health System, Barbara Ann Karmanos Cancer Institute and Karmanos Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738
Recruiting
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be give... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Clinical Trial Site, Detroit, Michigan
Conditions: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Register for Updates
Integrating the Youth Nominated Support Team (YST) With CBT for Black Youth With Acute Suicide Risk
NCT06941311
Recruiting
The investigators are modifying and testing the preliminary effectiveness and implementation of the combination of two psychosocial interventions, Cognitive Behavioral Therapy for Suicide Prevention (CBT-SP) and the computer-assisted version of the Youth-Nominated Support Team (eYST). This registration will be for Aim 2 and a pilot randomized clinical trial for Aim 3 will be registered separately. In this phase of the study, CBT-SP+eYST will be tested in an initial open trial (number of youth=6... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/03/2025
Locations: Children's Hospital of Michigan (CHM) Emergency Department, Detroit, Michigan +1 locations
Conditions: Suicide Prevention
Register for Updates
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541
Recruiting
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Richter's Syndrome (RS): * epcoritamab + lenal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Henry Ford Medical Group, Detroit, Michigan
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Ascension St. John, Detroit, Michigan
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
NCT05858320
Recruiting
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Henry Ford Hospital and Health System, Detroit, Michigan
Conditions: Heart Failure
Register for Updates
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210
Recruiting
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Small Cell Lung Cancer
Register for Updates
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236
Recruiting
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Platinum-resistant Ovarian Cancer
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
Recruiting
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Relapsed or Refractory T Cell Lymphoma
Register for Updates
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
NCT05866081
Recruiting
This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Stone, Kidney, Stone Ureter
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/30/2025
Locations: Ascension Saint John Hospital, Detroit, Michigan
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Karmanos Cancer Institiute, Detroit, Michigan
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates